The TDR Three Key Takeaways regarding Psychedelic Therapy Advancements and Alberta: Psychedelic therapy gains legal and insurance acceptance in Alberta. Psilocybin and MDMA treatments expand
The TDR Three Key Takeaways regarding Lykos Therapeutics and PTSD Therapy: Lykos Therapeutics achieves a major milestone with Phase 2 trials in Europe. MDMA-assisted therapy
The TDR Three Key Takeaways regarding Right to Try and Psychedelics: Psychedelic therapies’ potential blocked by DEA under Right to Try law. Research supports psychedelics’
The TDR Three Key Takeaways Regarding MindBio’s MB22001 and Sleep Quality: MindBio’s study identifies MB22001 as a promising sleep enhancer. Prior to this study, the
The TDR Three Key Takeaways regarding Ayahuasca and DEA: Ayahuasca’s role in religious practices gains recognition by the DEA. DEA acknowledges ayahuasca’s role in Native
The TDR Three Key Takeaways regarding Psychedelic Studies and LSD Microdosing: LSD microdosing highlighted as a promising sleep enhancer in new study. Experimental evidence points
The TDR Three Key Takeaways for Numinus and Cybin’s Phase 3 Study of CYB003: Numinus being selected by Cybin to conduct research trials validates its
The TDR Takeaways on the Regulatory Review Psychedelic Thought Leader Essays: The initial portions of six scholarly essays on psychedelics, written by academics from various
The TDR Three Takeaways for Psychedelic Therapy in California: Senate Bill 1012 propels psychedelic therapy forward, emphasizing safety and professionalism. Psychedelic therapy is separated from
The TDR Three Takeaways for DEA Hearings on psychedelics: The upcoming DEA hearing on June 10, 2024, will determine the classification of two hallucinogens, potentially